F-group (family)
206.1.1.7 PI3_PI4_kinase
Ligands and drugs
784
Member domains
396
with ligand contacts (≤ 4 Å)
50.5% of members
338
with DrugDomain annotations
43.1% of members
131
with a DrugBank compound
16.7% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 206.1.1.7 belongs to X-group 206 Protein kinase/SAICAR synthase/ATP-grasp, which binds 10.2 ligand superclasses per 20 proteins, broader than 96% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB06836 | 093 | N-(5-{4-Chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide | 19 |
| DB00171 | ATP | ATP | 6 |
| DB12015 | 1LT | Alpelisib | 6 |
| DB12010 | — | Fostamatinib | 5 |
| DB15275 | X3N | Inavolisib | 5 |
| DB16833 | ADP | Adenosine disphosphate | 4 |
| DB00201 | — | Caffeine | 3 |
| DB06831 | 039 | 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE | 3 |
| DB08059 | KWT | Wortmannin | 3 |
| DB11663 | GD9 | Pictilisib | 3 |
| DB12483 | — | Copanlisib | 3 |
| DB17046 | X6K | PI-103 | 3 |
| DB02375 | MYC | Myricetin | 2 |
| DB02656 | LY2 | LY-294002 | 2 |
| DB04216 | QUE | Quercetin | 2 |
| DB05552 | — | TG100-115 | 2 |
| DB09054 | 40L | Idelalisib | 2 |
| DB11666 | SD5 | Buparlisib | 2 |
| DB11952 | — | — | 2 |
| DB11974 | ML9 | PF-04691502 | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| 093 | N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE | 18 |
| ATP | ADENOSINE-5'-TRIPHOSPHATE | 15 |
| ADP | ADENOSINE-5'-DIPHOSPHATE | 11 |
| 1LT | (2S)-N~1~-{4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide | 10 |
| CL | CHLORIDE ION | 10 |
| MGmetal | MAGNESIUM ION | 8 |
| YNZ | (2S)-N~1~-[(4P)-2-tert-butyl-4'-methyl[4,5'-bi-1,3-thiazol]-2'-yl]pyrrolidine-1,2-dicarboxamide | 6 |
| NAmetal | SODIUM ION | 5 |
| X3N | N~2~-{(4S,11aP)-2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}-L-alaninamide | 5 |
| 090 | N-(2,3-DIHYDRO-7,8-DIMETHOXYIMIDAZO[1,2-C] QUINAZOLIN-5-YL)NICOTINAMIDE | 4 |
| 5H5 | (2S)-2-({2-[1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}oxy)propanamide | 4 |
| J82 | 2-[2-(2-METHYL-2,3-DIHYDRO-INDOL-1-YL)-2-OXO-ETHYL]-6-MORPHOLIN-4-YL-3H-PYRIMIDIN-4-ONE | 4 |
| YO4 | 2-({(1R)-1-[2-(4,4-dimethylpiperidin-1-yl)-3,6-dimethyl-4-oxo-4H-1-benzopyran-8-yl]ethyl}amino)benzoic acid | 4 |
| YOR | N-{(3S)-3-(2-methylphenyl)-6-[(oxetan-3-yl)amino]-1-oxo-2,3-dihydro-1H-isoindol-4-yl}-1-benzothiophene-3-carboxamide | 4 |
| ZWE | N-(2-aminopyrimidin-5-yl)-N'-[(1R)-1-(5,7-difluoro-3-methyl-1-benzofuran-2-yl)-2,2,2-trifluoroethyl]urea | 4 |
| GD9 | 2-(1H-indazol-4-yl)-6-{[4-(methylsulfonyl)piperazin-1-yl]methyl}-4-morpholin-4-yl-thieno[3,2-d]pyrimidine | 3 |
| IHP | INOSITOL HEXAKISPHOSPHATE | 3 |
| Kmetal | POTASSIUM ION | 3 |
| X6K | 3-(4-MORPHOLIN-4-YLPYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDIN-2-YL)PHENOL | 3 |
| 039 | 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE | 2 |